Cytokinetics, Incorporated
NASDAQ:CYTKBiotechnology
+$2.90 today
- Market cap
- $7.15B
- Beta
- 0.43
- P/E (TTM)
- -11.6
- EPS (TTM)
- -$6.73
Volume 1.59M
Average 2.37M
CYTK Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Cytokinetics, IncorporatedNASDAQ: CYTK
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $35.71M rose 29.7% year over year, ahead of the -5.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 17.5% from the prior quarter. Over 3 fiscal years it compounded at +32.9% a year.
Context
- Stock-based compensation amounted to 127.5% of revenue in FY2025, down 402.1 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +29.7% holds above the trailing-twelve-month pace of -5.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 112.29M USD
- Year-over-year change
- +14.8%
- 4-year CAGR
- +43.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 112.29M | +14.8% |
| FY2024 | 2024-12-31 | 97.84M | +35.8% |
| FY2023 | 2023-12-31 | 72.07M | +50.6% |
| FY2022 | 2022-12-31 | 47.85M | +78.3% |
| FY2021 | 2021-12-31 | 26.83M | — |
Stock-Based Compensation vs competitors
How CYTK compares with its peers on the latest reported figures
- CYTK's LTM Jun 2026 stock-based compensation of $96.8M is the largest of the 3 companies compared; the peer median is $9.6M.
- Its year-over-year change of -5.7% is the highest of 2, against a peer median of -28.1%.
- Stock-based compensation amounts to 136.4% of revenue for CYTK, versus a peer median of 2578.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $96.8M | -5.7% | +32.9% | 136.4% | |
| LTM Mar 2026 | $11.51M | -28.1% | +4.4% | 5116.0% | |
| FY2025 | $7.68M | — | — | 41.2% | |
| — | — | — | — | — | |
| Peer median (excluding CYTK) | $9.6M | -28.1% | +4.4% | 2578.6% | |
Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (215.31M) | (388.96M) | (526.24M) | (589.53M) | (784.96M) |
| Depreciation & Amortization | 2.28M | 5.81M | 11.89M | 9.53M | 10.13M |
| Deferred Income Tax | 2.84M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 26.83M | 47.85M | 72.07M | 97.84M | 112.29M |
| Change in Working Capital | 8.46M | (24.7M) | 3.09M | 35.66M | (35.63M) |
| Accounts Receivables | (47.4M) | 56.67M | (1.14M) | (15.37M) | (1.11M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.06M | 4.52M | (3.48M) | (4.48M) | 2.66M |
| Other Working Capital | 54.8M | (85.9M) | 7.71M | 55.51M | (37.18M) |
| Other Non-Cash Items | 32.38M | 60.48M | 24.87M | 50.6M | 188.16M |
| Operating Cash Flow | (142.52M) | (299.52M) | (414.33M) | (395.89M) | (510.01M) |
| Capital Expenditures | (48.87M) | (11.34M) | (1.42M) | (3.91M) | (24.81M) |
| Acquisitions (Net) | 98.91M | 250.8M | 0 | 0 | 0 |
| Purchases of Investments | (525.04M) | (855.39M) | (635.21M) | (1.29B) | (1.06B) |
| Sales of Investments | 426.14M | 604.59M | 875.88M | 744.23M | 1.11B |
| Other Investing Activities | (98.91M) | (250.8M) | 0 | 0 | (5M) |
| Investing Cash Flow | (147.78M) | (262.13M) | 239.25M | (553.1M) | 16.67M |
| Debt Repayment | 0 | 334.66M | (858K) | (9.62M) | 490.95M |
| Common Stock Issued | 312.05M | 17.54M | 164.23M | 706.84M | 35.98M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.93M | 163.96M | 57.94M | 233.39M | (2.47M) |
| Financing Cash Flow | 319.98M | 516.17M | 221.32M | 930.61M | 524.46M |
| Effect of Forex Changes | 0 | 0 | (20K) | 209K | (715K) |
| Net Change in Cash | 29.68M | (45.48M) | 46.22M | (18.17M) | 30.4M |
| Free Cash Flow | (191.39M) | (310.85M) | (415.75M) | (399.8M) | (534.82M) |
Cytokinetics, Incorporated
NASDAQ:CYTK
Intrinsic Alpha fair value
Locked
Current Price
$51.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.